Skip to content
Pharma Observatory a Scientist.com platform

Organization (Other)

Daihong Liu

ClinicalTrials.gov lists Daihong Liu as lead sponsor of 13 trials. It has 12 active development programs and 3 approved assets.

Other
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Disease areas Disease areas 8 Trials by start year as sponsor or collaborator Trials by start year as sponsor or collaborator 2 Active development programs Active development programs 12 Approved assets Approved assets 3 Journals published in Journals published in 24 Latest dated events Latest dated events 13 Biomarker capability evidence Biomarker capability evidence 50 Disease areas Disease areas 8 Trials by start year as sponsor or collaborator Trials by start year as sponsor or collaborator 2 Active development programs Active development programs 12 Approved assets Approved assets 3 Journals published in Journals published in 24 Latest dated events Latest dated events 13 Biomarker capability evidence Biomarker capability evidence 50

Rows recorded per section (log scale)

17 sections measured, none recorded

This page covers Daihong Liu: 13 lead-sponsored trials and 0 legal-entity registrations.

Get the Daihong Liu report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (8)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Lymphoma 2
Lymphoma, B-Cell 2
Lymphoma, Non-Hodgkin 2
Graft vs Host Disease 1
Leukemia, Myeloid, Acute 1

Showing 5 of 8 disease areas.

Start your 14-day trial Email me all 8 disease areas as a PDF

Trials by start year as sponsor or collaborator (2)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 1
2025 12

No forecast is made for this organization: it averages 2.6 trial starts a year over the five years to September, under the 5 a year the method needs.

Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

Active development programs (12)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
CD22/CD19 CAR-T cell immunotherapy Lymphoma Phase 2 1
CD22/CD19 CAR-T cell immunotherapy Lymphoma, Non-Hodgkin Phase 2 1
CD22/CD19 CAR-T cell immunotherapy Lymphoma, B-Cell Phase 2 1
CAR-T Cell Therapy + Chidamide and PD-1 Inhibitor Maintenance Lymphoma Phase 2 1
CAR-T Cell Therapy + Chidamide and PD-1 Inhibitor Maintenance Lymphoma, Non-Hodgkin Phase 2 1

Showing 5 of 12 active programs.

Start your 14-day trial Email me all 12 active programs as a PDF

Approved assets (3)

Shown in this order: max phase first.

Approved assets
Drug Trials
Anti Thymocyte Globulin 2
Ruxolitinib 1
METHYLPREDNISOLONE 1

Journals published in (24)

Shown in this order: most published in first.

Journals published in
Journal Publications
International journal of hematology 2
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 1
American journal of hematology 1
Annals of hematology 1
BMC cancer 1

Showing 5 of 24 journals.

Start your 14-day trial Email me all 24 journals as a PDF

Latest dated events (13)

Shown in this order: newest first.

Latest dated events
Date Event Source
2026-08-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2025-12-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2025-09-29 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2025-09-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2025-06-30 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Showing 5 of 13 events.

Start your 14-day trial Email me all 13 events as a PDF

Biomarker capability evidence (50)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
BCL2 Trial sponsor Named in trial inclusion criteria
BCL2 Trial sponsor Named in trial inclusion criteria
BCL6 Trial sponsor Named in trial inclusion criteria
BCL6 Trial sponsor Named in trial inclusion criteria
CD19 Trial sponsor Named in trial inclusion criteria

Showing 5 of 50 evidence rows.

Start your 14-day trial Email me all 50 evidence rows as a PDF

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sponsor delivery record, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.